Semaglutide Hydrogel Tested in Rats

A 2026 preclinical study tested sustained-release semaglutide formulations in diet-induced obese rats, not people. The researchers used a thermosensitive hydrogel and a micro-needle jet injection device, then compared the sustained system with a non-sustained formulation. One hydrogel formulation, GT10 50, was associated with continued weight loss over 20 days in the rat model^[1]. The experiment cannot establish human weight-loss efficacy, an appropriate human dose, or safety in patients.

What the delivery system tested

The paper describes a series of semaglutide-loaded sustained-release formulations. Its release system was based on Poloxamer 407, also called P407. The material underwent a temperature-dependent sol-gel transition: it remained injectable at a lower temperature, then formed a solid gel at body temperature to restrict drug release. Adding semaglutide did not disrupt that transition^[1]. This is a formulation result. It does not show that a hydrogel product is approved for clinical use.

The formulation was highly viscous, so the investigators used a micro-needle jet injection device to disperse it at delivery. They assessed physicochemical properties and in vitro release behavior before evaluating biocompatibility and drug effects in rats. The PubMed record reports consistent device delivery and no severe inflammation in the tested setting^[1]. That local finding is limited to the materials, device, animals, and observation period studied. It is not a general safety finding for people.

The named active formulation was GT10 50. The accessible primary record does not define every component encoded by that name, report the animal group counts, or provide enough information to reconstruct the formulation. It also does not state in the abstract whether allocation was randomized or outcome assessment was blinded. Those missing details matter when judging how reproducible the findings are. They should not be filled in from the formulation name or from unrelated hydrogel studies.

The pharmacokinetic readout

The sustained system changed semaglutide exposure in the rats. The authors report a half-life of 15 hours, compared with the non-sustained control, and a time to maximum concentration that moved from 8 hours to 24 hours. They also report maintaining effective drug levels through day 6^[1]. These are pharmacokinetic observations in this rat experiment. They are not a human dosing interval and do not support changing the schedule of an approved semaglutide product.

The comparator is important. The paper used a non-sustained semaglutide formulation to assess whether the hydrogel changed the duration of exposure and the persistence of measured effects. That design can test the delivery concept inside the model. It does not compare the experimental hydrogel with current clinical semaglutide presentations in patients, and it cannot determine whether a longer-release depot would improve adherence or outcomes in practice.

What happened in the DIO rats

In the diet-induced obesity model, GT10 50 produced continued weight loss over 20 days while the non-sustained formulation reached the plateau described by the authors^[1]. Here, plateau refers to the pattern observed in these rats under this experimental protocol. It is not a clinical definition of a human weight-loss plateau, a reason to alter treatment, or evidence that a depot formulation would restart weight loss in a person.

Researchers also measured serum total cholesterol, alanine aminotransferase, and aspartate aminotransferase. The abstract reports lower total cholesterol and AST at p < 0.01, with lower ALT at p < 0.05. The authors interpreted those results as improvements in dyslipidemia and liver injury in the rat model^[1]. A serum-marker change is not the same as a demonstrated clinical benefit, and the record does not provide absolute values or a human comparison.

Glucose tolerance testing was another reported endpoint. The authors state that the formulation alleviated hyperglycemia without hypoglycemia in the tested rats^[1]. That result describes the study conditions only. It cannot estimate hypoglycemia risk in people, particularly those taking insulin or an insulin secretagogue. The current US Wegovy label warns that those combinations may increase hypoglycemia risk^[2].

How this differs from approved semaglutide

The experimental hydrogel should not be confused with an approved presentation. The current US Wegovy prescribing information lists semaglutide injection solutions in pens or syringes and semaglutide tablets. It does not list a P407 thermosensitive hydrogel or a micro-needle jet delivery system^[2]. The rat paper therefore concerns an investigational delivery platform, even though semaglutide itself is an established prescription medicine.

Approved-product evidence and this formulation experiment answer different questions. The label describes clinical indications, dosage forms, contraindications, and warnings for products reviewed by the FDA. The animal paper asks whether a gel depot can alter release and measured effects in rats. Readers looking for established human evidence should use the semaglutide research overview rather than translate the rat pharmacokinetics into personal use.

What we don't yet know

This study does not establish whether GT10 50 can be manufactured consistently at clinical scale, remain stable during storage, or be delivered acceptably in people. It does not establish a human dose or dosing frequency. Nor does it tell us whether a depot could be removed or managed if a prolonged adverse reaction occurred. Human studies would need to characterize local tissue effects and systemic exposure before testing weight outcomes.

The primary record also leaves methodological questions that the abstract cannot answer, including exact group sizes and the handling of missing observations. Until fuller methods and independent replication are available, the most defensible conclusion is narrow: a P407-based hydrogel prolonged semaglutide exposure and sustained several measured effects in a rat model. It offers a drug-delivery research direction, not a new treatment option.

Do not use the reported rat timings to change a prescription or seek an unapproved depot formulation. Anyone concerned about a slowing response to semaglutide treatment should discuss it with a qualified healthcare professional who can assess the approved product, the treatment history, and relevant medical factors.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.